1-β-arabinofuranosylcytosine in therapy of leukemia: Preclinical and clinical overview

This publication has 48 references indexed in Scilit:

• The Toxicity of Cytarabine
  Drug Safety, 1990
• High‐dose ARA‐C (HiDAC) plus asparaginase in elderly patients with acute non‐lymphocytic leukemia: A pilot multicentric study by the Italian cooperative group GIMEMA
  European Journal of Haematology, 1989
• Intermediate and high dose Ara-C and m-AMSA for remission induction and consolidation treatment of patients with acute myeloid leukemia: an EORTC leukemia cooperative group phase II study
  European Journal of Cancer and Clinical Oncology, 1988
• Results of induction and consolidation treatment with intermediate and high‐dose cytosine arabinoside and m‐Amsa of patients with poor‐risk acute myelogeneous leukaemia
  European Journal of Haematology, 1988
• Allogeneic bone marrow transplantation versus intensification chemotherapy for acute myelogenous leukaemia in first remission: a prospective controlled trial
  British Journal of Haematology, 1988
• Does the metabolite uracil arabinoside inhibit cytosine arabinoside (Ara‐C) penetration into the cerebrospinal fluid during high‐dose Ara‐C therapy?
  Scandinavian Journal of Haematology, 1986
• Ara‐C syndrome during low‐dose continuous infusion therapy
  Medical and Pediatric Oncology, 1985
• Prediction of response of acute nonlymphocytic leukaemia to therapy with ‘high dose’ cytosine arabinoside
  British Journal of Haematology, 1984
• Central nervous system toxicity of high‐dose cytosine arabinoside
  Medical and Pediatric Oncology, 1983
• Letter: neuropathy due to cytosine arabinoside.
  BMJ, 1974